Ranbaxy Laboratories Chairman, Tajendra Khanna, in a recent seminar organised by Guru Gobind Singh Indraprastha University on 'Managing Corporate Reputation', spoke about the comapny's plan of foraying into the herbal drugs market. He said that their products would create stiff competition for the key player in the market - Dabur, which has 60 per cent market share. The company plans to market a few herbal drugs in the forthcoming months, whose details are available in their corporate website. The company's products have already shown remarkable progress in the US market where the sales has increased from $15 million in 1998 to $296 million in 2002 and, the figures are pegged at $400 million for this year. The worldwide sales for the herbal drugs this year is expected to be around $930 million, while the company's Indian operations predict sales at around $190 million.